China's CAR-T Medical Tourism: Low Prices Attract Global Patients

China is emerging as a new hub for medical tourism offering advanced cancer treatments. Its main weapon is CAR-T therapy. This treatment uses genetic modification technology to turn a patient’s own immune cells into specialized cancer-killing agents, making it one of the most promising breakthroughs in oncology. However, in many countries, the therapy is either difficult to provide or prohibitively expensive, hindering widespread adoption.

How CAR-T Therapy Works

CAR-T therapy begins with collecting T cells from a patient’s blood and genetically modifying them in a laboratory. The modification creates chimeric antigen receptors (CARs) on the T cells’ surface that bind to specific proteins on cancer cells. The genetically modified cells are then multiplied in large numbers and reinfused into the patient. CAR-T cells actively hunt down and destroy cancer cells that carry the target antigen.

This therapy has shown remarkable efficacy against blood cancers such as lymphoblastic leukemia and diffuse large B-cell lymphoma. Research into its application for solid tumors is ongoing, but as of now, its use is primarily focused on blood cancers.

Patient Flow Driven by Price Differences

Two main reasons patients seek treatment abroad are access to advanced therapies and cost. The price disparity for CAR-T therapy is especially stark. According to the American Cancer Society, a single infusion of CAR-T cells in the United States costs between $300,000 and $475,000. In Japan, although the high-cost medical expense system is applicable, patient burdens remain significant, and in some cases, the therapy is not covered by insurance.

In contrast, the cost in China is about $150,000 to $180,000—less than half the U.S. price. China’s drug regulatory authority recently approved a marketing application for an immunotherapy priced under 300,000 yuan (approximately 6 million yen), suggesting prices could drop further. This price gap is a huge draw for patients in countries with limited insurance coverage or those paying out of pocket.

Expansion of China’s Medical Tourism Market

According to New York-based market research firm Market Research Future, China’s medical tourism market is projected to grow from $1.3 billion in 2025 to $3.4 billion by 2035. This growth is supported not only by CAR-T therapy but also by advanced radiation therapies such as proton beam therapy and heavy ion therapy.

Jeroen Groenewegen-Lau, an analyst at the Mercator Institute for China Studies, notes that while many advanced treatments are being developed in China, they are often too cutting-edge for the existing domestic healthcare system and patients’ ability to pay. Therefore, integrating into the international medical system serves China’s interests. In other words, China appears to be pursuing a strategy of making high-level medical care economically viable by attracting overseas patients, when the domestic market alone may not achieve profitability.

Challenges and Risks

While low prices are attractive to patients, challenges remain. Treatment abroad involves risks such as language barriers, difficulties in post-operative follow-up, and inadequate legal protection. CAR-T therapy in particular is known for severe side effects like cytokine release syndrome (CRS) and neurotoxicity, necessitating careful judgment when receiving treatment in environments where emergency response systems may not be fully equipped.

Furthermore, international trust in China’s drug review system and clinical trial quality management remains a topic of debate. Some treatments may be offered without approval from the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA), requiring patients to thoroughly gather information and assess risks.

Editorial Opinion

In the short term, China’s low-cost CAR-T therapy could bring structural change to the Western medical tourism market. An increase in U.S. patients facing high out-of-pocket costs and choosing to travel to China for treatment is expected. This trend could pressure national health insurance systems to compete on price.

From a long-term perspective, as Chinese CAR-T therapies expand internationally, frameworks for technology transfer and international joint clinical trials may grow. However, challenges such as standardizing quality assurance and harmonizing side-effect management systems across borders will also emerge. The degree of transparency and data disclosure China provides will be key to earning trust.

Our editorial view is that more information disclosure and evaluation systems by third-party organizations are necessary to mitigate the risks of patients choosing treatments based solely on price. Medical tourism is not just a business opportunity; it is a matter directly linked to patients’ lives. The construction of an international framework that guarantees treatment quality and safety will determine the sustainability of future growth.

References

• Solidot: China’s Cancer Medical Tourism — Published 2026-06-12
• Slashdot: China Lures Foreign Patients With Cutting-Edge, Cheap Medical Care — Published 2026-06-11